{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T21:10:38Z","timestamp":1787346638728,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.msard.2024.106163","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T03:21:14Z","timestamp":1730863274000},"page":"106163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Progressive multifocal leukoencephalopathy associated with sphingosine-1-phosphate receptor modulators: A large case series"],"prefix":"10.1016","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5561-6940","authenticated-orcid":false,"given":"David","family":"Croteau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela A.","family":"Pimentel Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Baldassari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Brinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2024.106163_bib0001","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/01.nrl.0000250948.04681.96","article-title":"Review of progressive multifocal leukoencephalopathy and natalizumab","volume":"12","author":"Aksamit","year":"2006","journal-title":"Neurologist"},{"issue":"18","key":"10.1016\/j.msard.2024.106163_bib0005","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1212\/01.WNL.0000287431.88658.8b","article-title":"Updated research nosology for HIV-associated neurocognitive disorders","volume":"69","author":"Antinori","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.106163_bib0006","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-3-031-04402-1_7","article-title":"Rituximab-associated progressive multifocal leukoencephalopathy: a twenty-year update","volume":"184","author":"Bennett","year":"2022","journal-title":"Cancer Treat Res."},{"issue":"4","key":"10.1016\/j.msard.2024.106163_bib0009","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s13365-016-0427-6","article-title":"Reassessing the risk of natalizumab-associated PML","volume":"22","author":"Berger","year":"2016","journal-title":"J. Neurovirol."},{"issue":"15","key":"10.1016\/j.msard.2024.106163_bib0007","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"issue":"20","key":"10.1016\/j.msard.2024.106163_bib0008","doi-asserted-by":"crossref","first-page":"e1815","DOI":"10.1212\/WNL.0000000000005529","article-title":"Progressive multifocal leukoencephalopathy after fingolimod treatment","volume":"90","author":"Berger","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2024.106163_bib0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease","volume":"17","author":"Cortese","year":"2021","journal-title":"Nat. Rev. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2024.106163_bib0011","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1177\/13524585221102584","article-title":"Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: up to 5\u2009years of follow-up in the DAYBREAK open-label extension trial","volume":"28","author":"Cree","year":"2022","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2024.106163_bib0012","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s13365-015-0316-4","article-title":"Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"21","author":"Dong-Si","year":"2015","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.msard.2024.106163_bib0003","unstructured":"European medical agency. Ponvory EMA assessment report. March 25, 2021. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/ponvory-epar-public-assessment-report_en.pdf. Accessed December 12, 2023."},{"key":"10.1016\/j.msard.2024.106163_bib0013","doi-asserted-by":"crossref","first-page":"59","DOI":"10.25259\/SNI-4-2019","article-title":"Anti-John Cunningham virus antibody index levels in multiple sclerosis patients treated with rituximab, fingolimod, and dimethyl fumarate","volume":"10","author":"Farley","year":"2019","journal-title":"Surg. Neurol. Int."},{"issue":"1","key":"10.1016\/j.msard.2024.106163_bib0014","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ana.24051","article-title":"Progressive multifocal leukoencephalopathy after natalizumab discontinuation","volume":"75","author":"Fine","year":"2014","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2024.106163_bib0016","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1212\/WNL.0b013e318245d2d0","article-title":"Risk stratification and patient counseling for natalizumab in multiple sclerosis","volume":"78","author":"Fox","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2024.106163_bib0015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1212\/CPJ.0000000000000567","article-title":"Lymphopenia and DMTs for relapsing forms of MS: considerations for the treating neurologist","volume":"9","author":"Fox","year":"2019","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.msard.2024.106163_bib0017","unstructured":"Gilenya (fingolimod) Prescribing Information. Novartis Pharmaceuticals Corporation. East Hanover, NJ. Updated June 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/022527s038lbl.pdf. Accessed November 30, 2023."},{"issue":"Suppl C","key":"10.1016\/j.msard.2024.106163_bib0018","doi-asserted-by":"crossref","first-page":"C40","DOI":"10.1016\/S0149-2918(98)80007-6","article-title":"Limitations and strengths of spontaneous reports data","volume":"20","author":"Goldman","year":"1998","journal-title":"Clin. Ther."},{"issue":"8","key":"10.1016\/j.msard.2024.106163_bib0019","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11910-017-0771-9","article-title":"Immunosenescence: the role of aging in the predisposition to neuro-infectious complications arising from the treatment of multiple sclerosis","volume":"17","author":"Grebenciucova","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"11","key":"10.1016\/j.msard.2024.106163_bib0020","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.msard.2024.106163_bib0021","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2024.106163_bib0022","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2024.106163_bib0023","first-page":"1","article-title":"Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate","author":"Lyons","year":"2022","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"2","key":"10.1016\/j.msard.2024.106163_bib0024","first-page":"117","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2024.106163_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103995","article-title":"Use of natalizumab in persons with multiple sclerosis: 2022 update","volume":"65","author":"Morrow","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2024.106163_bib0026","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s13365-017-0561-9","article-title":"Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy","volume":"23","author":"Prosperini","year":"2017","journal-title":"J. Neurovirol."},{"issue":"1","key":"10.1016\/j.msard.2024.106163_bib0027","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/1941874412455338","article-title":"Neurological complications of transplantation: part I: hematopoietic cell transplantation","volume":"3","author":"Pruitt","year":"2013","journal-title":"Neurohospitalist"},{"issue":"4","key":"10.1016\/j.msard.2024.106163_bib0028","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40263-021-00798-w","article-title":"Sphingosine 1-phosphate receptor modulators for multiple sclerosis","volume":"35","author":"Roy","year":"2021","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.msard.2024.106163_bib0029","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1007\/s00415-021-10910-1","article-title":"Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature","volume":"269","author":"Sriwastava","year":"2022","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.106163_bib0030","doi-asserted-by":"crossref","first-page":"e1092","DOI":"10.1212\/NXI.0000000000001092","article-title":"COVID-19 infection in fingolimod- or siponimod-treated patients: case series","volume":"9","author":"Sullivan","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2024.106163_bib0031","unstructured":"Tecfidera (dimethyl fumarate) Prescribing Information. Biogen. Cambridge, MA. Updated March 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/204063s031lbl.pdf."},{"issue":"3","key":"10.1016\/j.msard.2024.106163_bib0032","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/acn3.51130","article-title":"Improving risk-stratification of natalizumab-associated PML","volume":"8","author":"Tugemann","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2024.106163_bib0033","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ana.22185","article-title":"Progressive multifocal leukoencephalopathy: can we reduce risk in patients receiving biological immunomodulatory therapies?","volume":"68","author":"Tyler","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2024.106163_bib0034","unstructured":"Tysabri (natalizumab) Prescribing Information. Biogen. Cambridge, MA. Updated October 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125104Orig1s980lbl.pdf."},{"key":"10.1016\/j.msard.2024.106163_bib0004","unstructured":"U.S Food and Drug Administration. Questions and answers on FDA's adverse event reporting system (FAERS). https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers. Accessed November 30, 2023."},{"key":"10.1016\/j.msard.2024.106163_bib37","unstructured":"U.S. Food and Drug Administration, Best practices in drug and biological product postmarket safety surveillance for FDA staff. November 2019. https:\/\/www.fda.gov\/media\/130216\/download. Accessed November 30, 2023."},{"issue":"4","key":"10.1016\/j.msard.2024.106163_bib0035","first-page":"e14764","article-title":"Risk of progressive multifocal leukoencephalopathy in multiple sclerosis patient treated with Natalizumab: a systematic review","volume":"13","author":"Vivekanandan","year":"2021","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.msard.2024.106163_bib0036","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/jnnp-2020-324534","article-title":"Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications","volume":"92","author":"Wijburg","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824007399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824007399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:55:04Z","timestamp":1757357704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824007399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":36,"alternative-id":["S2211034824007399"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.106163","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progressive multifocal leukoencephalopathy associated with sphingosine-1-phosphate receptor modulators: A large case series","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.106163","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106163"}}